Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the interest coverage ratio high or low?
The interest coverage ratio of -9.33x is 18% above its 4-year average of -11.42x, near the high end of its 4-year range (-980.35x–-7.57x).
8.90% above its 12-month average of -10.24x.
Reported quarterly interest coverage; no daily interpolation. Q2 FY2026 (2026-06-30): -10.69x.
INTEREST COVERAGE RATIO
-9.33x
INTEREST COVERAGE RATIO AVG TTM
-10.24x
INTEREST COVERAGE RATIO AVG 3Y
-10.15x
INTEREST COVERAGE RATIO AVG 5Y
N/A
INTEREST COVERAGE RATIO AVG 10Y
N/A
INTEREST COVERAGE RATIO AVG 15Y
N/A
INTEREST COVERAGE RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+8.90%
CURRENT VS 3Y AVG
+8.06%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-5.79x
median of 488 covered companies
CURRENT VS SECTOR MEDIAN
-61.14%
vs the sector median at left
Rhythm Pharmaceuticals, Inc.
Market Cap
$6.23B
Interest Coverage Ratio
-9.33x
TTM Avg
-10.24x
3Y Avg
-10.15x
5Y Avg
N/A
Market Cap
$6.49B
Interest Coverage Ratio
1.75x
TTM Avg
1.35x
3Y Avg
1.23x
5Y Avg
1.08x
Market Cap
$6.50B
Interest Coverage Ratio
15.74x
TTM Avg
19.48x
3Y Avg
15.56x
5Y Avg
15.56x
Market Cap
$5.94B
Interest Coverage Ratio
10.01x
TTM Avg
10.01x
3Y Avg
9.97x
5Y Avg
7.31x
Market Cap
$6.58B
Interest Coverage Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$5.92B
Interest Coverage Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$6.66B
Interest Coverage Ratio
193.28x
TTM Avg
199.58x
3Y Avg
145.92x
5Y Avg
155.47x
| NAME | MARKET CAP | INTEREST COVERAGE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Rhythm Pharmaceuticals, Inc. (RYTM) | $6.23B | -9.33x | -10.24x | -10.15x | N/A |
| GRAIL Inc. (GRAL)vs › | $6.00B | N/A | N/A | N/A | N/A |
| Amneal Pharmaceuticals, Inc. (AMRX)vs › | $6.49B | 1.75x | 1.35x | 1.23x | 1.08x |
| Lantheus Holdings, Inc. (LNTH)vs › | $6.50B | 15.74x | 19.48x | 15.56x | 15.56x |
| Immunovant, Inc. (IMVT)vs › | $6.55B | N/A | N/A | N/A | N/A |
| Ligand Pharmaceuticals Incorporated (LGND)vs › | $5.94B | 10.01x | 10.01x | 9.97x | 7.31x |
| Hims & Hers Health, Inc. (HIMS)vs › | $6.58B | N/A | N/A | N/A | N/A |
| Iovance Biotherapeutics, Inc. (IOVA)vs › | $5.92B | N/A | N/A | N/A | N/A |
| Chemed Corporation (CHE)vs › | $6.66B | 193.28x | 199.58x | 145.92x | 155.47x |
| Kiniksa Pharmaceuticals International, plc (KNSA)vs › | $5.76B | N/A | N/A | N/A | N/A |
Interest Coverage
-9.3x
Debt/Equity
0.02
Current Ratio
3.45
Formula: Interest Coverage = EBIT / Interest Expense
Reference ranges:
Note: Interest coverage should be compared with historical interest expense, operating income, and industry capital structure.
Interest Coverage = EBIT / Interest Expense
The interest coverage ratio measures operating earnings relative to interest expense.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | INTEREST COVERAGE RATIO |
|---|---|
| 2026-06-30 | -10.69x |
| 2026-03-31 | -11.43x |
| 2025-12-31 | -10.20x |
| 2025-09-30 | -11.10x |
| 2025-06-30 | -7.79x |
| 2025-03-31 | -8.69x |
| 2024-12-31 | -7.57x |
| 2024-09-30 | -8.37x |
| 2024-06-30 | -8.79x |
| 2024-03-31 | -29.42x |
| 2023-12-31 | -9.07x |
| 2023-09-30 | -13.96x |
| 2023-06-30 | -14.11x |
| 2023-03-31 | -17.16x |
| 2022-12-31 | -13.98x |
| 2022-09-30 | -18.31x |
| 2022-06-30 | -980.35x |
